Personalized mRNA Vaccine Cuts Melanoma Recurrence Risk by 42% in Phase 3 Trial
Phase 3 trial results presented at ESMO 2026 show that adding personalized mRNA vaccine intismeran to pembrolizumab reduces melanoma recurrence ...
Tag: intismeran
POPULAR NEWS
-
Sexual Violence and Unequal Screening Mark Health of Women on Illegal Gold Mining Sites in French Guiana
-
Sunlight Exposure Linked to Shifting Cancer Patterns Across China, Ecological Study Finds
-
Magnetic Gut Robot Delays Biologic Release
-
Rituximab Brings Only Transient Relief in Children With ROHHAD Syndrome